{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/RAPP/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-17T00:48:03.504Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":9631,"canonical_name":"Rapport Therapeutics, Inc.","cik":"0002012593","uei":null,"lei":null,"duns":null,"ticker":"RAPP"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":29},"count":29,"timeline":[{"ts":"2026-08-26","kind":"sec.filing","form_type":"4","title":"4 — Rapport Therapeutics, Inc. — 2026-08-26","url_slug":"/sec/cik-0002012593/4/0001193125-26-368244","accession_number":"0001193125-26-368244","importance":30},{"ts":"2026-08-25","kind":"sec.filing","form_type":"144","title":"144 — Rapport Therapeutics, Inc. — 2026-08-25","url_slug":"/sec/cik-0002012593/144/0001950047-26-008670","accession_number":"0001950047-26-008670","importance":30},{"ts":"2026-08-24","kind":"sec.filing","form_type":"144","title":"144 — Rapport Therapeutics, Inc. — 2026-08-24","url_slug":"/sec/cik-0002012593/144/0001950047-26-008594","accession_number":"0001950047-26-008594","importance":30},{"ts":"2026-08-20","kind":"sec.filing","form_type":"4","title":"4 — Rapport Therapeutics, Inc. — 2026-08-20","url_slug":"/sec/cik-0002012593/4/0001193125-26-359189","accession_number":"0001193125-26-359189","importance":30},{"ts":"2026-08-19","kind":"sec.filing","form_type":"144","title":"144 — Rapport Therapeutics, Inc. — 2026-08-19","url_slug":"/sec/cik-0002012593/144/0001950047-26-008426","accession_number":"0001950047-26-008426","importance":30},{"ts":"2026-08-05","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Rapport Therapeutics, Inc. — 2026-08-05","url_slug":"/sec/cik-0002012593/10-q/0001193125-26-333862","accession_number":"0001193125-26-333862","importance":45},{"ts":"2026-08-05","kind":"sec.filing","form_type":"8-K","title":"8-K — Rapport Therapeutics, Inc. — 2026-08-05","url_slug":"/sec/cik-0002012593/8-k/0001193125-26-333853","accession_number":"0001193125-26-333853","importance":35},{"ts":"2026-07-27","kind":"sec.insider.s","reporter":"Ceesay Abraham","title":"Chief Executive Officer","shares":2203,"price_per_share":42.107,"usd_value":92762,"security_title":"Common Stock","importance":35.092761721},{"ts":"2026-07-27","kind":"sec.insider.s","reporter":"Ceesay Abraham","title":"Chief Executive Officer","shares":7,"price_per_share":42.735,"usd_value":299,"security_title":"Common Stock","importance":35.000299145},{"ts":"2026-07-15","kind":"sec.filing","form_type":"4","title":"4 — Ceesay Abraham — 2026-07-15","url_slug":"/sec/cik-0001722140/4/0001193125-26-304786","accession_number":"0001193125-26-304786","importance":30},{"ts":"2026-07-14","kind":"sec.insider.s","reporter":"Ceesay Abraham","title":"Chief Executive Officer","shares":5481,"price_per_share":39.7217,"usd_value":217715,"security_title":"Common Stock","importance":35.2177146377},{"ts":"2026-07-14","kind":"sec.insider.s","reporter":"Ceesay Abraham","title":"Chief Executive Officer","shares":2729,"price_per_share":40.5724,"usd_value":110722,"security_title":"Common Stock","importance":35.1107220796},{"ts":"2026-06-30","kind":"sec.form144","reporter":"CHERYL GAULT","title":"Officer","shares":10000,"usd_value":403900,"security_title":"Common","approx_sale_date":"2026-06-30","accession_number":"0001950047-26-006648","importance":40.08078},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"Gault Cheryl","title":"Chief Operating Officer","shares":3792,"price_per_share":41.3934,"usd_value":156964,"security_title":"Common Stock","importance":35.1569637728},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"Gault Cheryl","title":"Chief Operating Officer","shares":3308,"price_per_share":42.1722,"usd_value":139506,"security_title":"Common Stock","importance":35.1395056376},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"Gault Cheryl","title":"Chief Operating Officer","shares":1900,"price_per_share":40.0914,"usd_value":76174,"security_title":"Common Stock","importance":35.07617366},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"Gault Cheryl","title":"Chief Operating Officer","shares":1000,"price_per_share":43.1547,"usd_value":43155,"security_title":"Common Stock","importance":35.0431547},{"ts":"2026-06-29","kind":"sec.form144","reporter":"Abraham N. Ceesay","title":"Officer","shares":99480,"usd_value":4017997,"security_title":"Common","approx_sale_date":"2026-06-29","accession_number":"0001958244-26-000411","importance":40.80359944},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Ceesay Abraham","title":"Chief Executive Officer","shares":7344,"price_per_share":39.7688,"usd_value":292062,"security_title":"Common Stock","importance":35.2920620672},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Ceesay Abraham","title":"Chief Executive Officer","shares":876,"price_per_share":40.3375,"usd_value":35336,"security_title":"Common Stock","importance":35.03533565},{"ts":"2026-06-10","kind":"sec.filing","form_type":"8-K","title":"8-K — Rapport Therapeutics, Inc. — 2026-06-10","url_slug":"/sec/cik-0002012593/8-k/0001193125-26-265841","accession_number":"0001193125-26-265841","importance":35},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — Rapport Therapeutics, Inc. — 2026-06-10","url_slug":"/sec/cik-0002012593/4/0001193125-26-266086","accession_number":"0001193125-26-266086","importance":30},{"ts":"2026-05-11","kind":"sec.insider.s","reporter":"Third Rock Ventures V, L.P.","title":null,"shares":133618,"price_per_share":40.244,"usd_value":5377323,"security_title":"Common Stock","importance":40.377322792},{"ts":"2026-05-11","kind":"sec.insider.s","reporter":"Third Rock Ventures GP V, LP","title":null,"shares":133618,"price_per_share":40.244,"usd_value":5377323,"security_title":"Common Stock","importance":40.377322792},{"ts":"2026-05-11","kind":"sec.insider.s","reporter":"TRV GP V, LLC","title":null,"shares":133618,"price_per_share":40.244,"usd_value":5377323,"security_title":"Common Stock","importance":40.377322792},{"ts":"2026-05-11","kind":"sec.insider.s","reporter":"Third Rock Ventures VI, L.P.","title":null,"shares":133618,"price_per_share":40.244,"usd_value":5377323,"security_title":"Common Stock","importance":40.377322792},{"ts":"2026-05-11","kind":"sec.insider.s","reporter":"Third Rock Ventures GP VI, L.P.","title":null,"shares":133618,"price_per_share":40.244,"usd_value":5377323,"security_title":"Common Stock","importance":40.377322792},{"ts":"2026-05-11","kind":"sec.insider.s","reporter":"TRV GP VI, LLC","title":null,"shares":133618,"price_per_share":40.244,"usd_value":5377323,"security_title":"Common Stock","importance":40.377322792},{"ts":"2026-05-08","kind":"sec.form144","reporter":"Third Rock Ventures V, L.P.","title":"10% Stockholder","shares":5018,"usd_value":202255,"security_title":"Common","approx_sale_date":"2026-05-08","accession_number":"0001974078-26-000173","importance":40.0404509}]}